Matthew D Alexander1, Daniel S Hippe2, Daniel L Cooke1, Danial K Hallam2, Steven W Hetts1, Helen Kim3, Michael T Lawton4, Laligam N Sekhar5, Louis J Kim5, Basavaraj V Ghodke2. 1. University of California San Francisco, Department of Radiology and Biomedical Imaging, San Francisco, California. 2. Uni-versity Washington, Department of Radiology, Seattle, Washington. 3. Univer-sity of California San Francisco, Depart-ment of Anesthesia and Perioperative Care, San Francisco, California. 4. University of California San Francisco, Department of Neurological Surgery, San Francisco, California. 5. University Washington, De-partment of Neurological Surgery, Seattle, Washington.
Abstract
BACKGROUND: High-risk components of brain arteriovenous malformations (BAVMs) can be targeted to reduce the risk of lesion rupture. OBJECTIVE: To evaluate targeted embolization of aneurysms against other means of treatment with a case-control analysis; we previously investigated this approach associated with BAVMs. METHODS: Retrospective analysis of patients with BAVMs was performed, identifying patients treated with intention to occlude only an aneurysm associated with a BAVM. For each targeted aneurysm embolization (TAE) patient identified, 4 control patients were randomly selected, controlling for rupture status, age, and Spetzler-Martin plus Lawton-Young supplemental score. Analysis was performed to compare rates of adverse events (hemorrhage, new seizure, and death) between the 2 groups. RESULTS: Thirty-two patients met inclusion criteria, and 128 control patients were identified, out of 1103 patients treated during the study period. Thirty-four adverse events occurred (15 ruptures, 15 new seizures, and 11 deaths) during the follow-up period (mean 1157 d for the TAE cohort and 1036 d for the non-TAE cohort). Statistically lower associations were noted for the TAE group for any adverse event (hazard ratio 0.28, P = .037) and the composite outcome of hemorrhage or new seizure (hazard ratio 0.20, P = .029). CONCLUSION: For BAVMs at high risk for surgical resection, TAE can be performed safely and effectively. Patients treated with TAE had better outcomes than matched patients undergoing other combinations of treatment. TAE can be considered for BAVMs with high operative risk prior to radiosurgery or when no other treatment options are available.
BACKGROUND: High-risk components of brain arteriovenous malformations (BAVMs) can be targeted to reduce the risk of lesion rupture. OBJECTIVE: To evaluate targeted embolization of aneurysms against other means of treatment with a case-control analysis; we previously investigated this approach associated with BAVMs. METHODS: Retrospective analysis of patients with BAVMs was performed, identifying patients treated with intention to occlude only an aneurysm associated with a BAVM. For each targeted aneurysm embolization (TAE) patient identified, 4 control patients were randomly selected, controlling for rupture status, age, and Spetzler-Martin plus Lawton-Young supplemental score. Analysis was performed to compare rates of adverse events (hemorrhage, new seizure, and death) between the 2 groups. RESULTS: Thirty-two patients met inclusion criteria, and 128 control patients were identified, out of 1103 patients treated during the study period. Thirty-four adverse events occurred (15 ruptures, 15 new seizures, and 11 deaths) during the follow-up period (mean 1157 d for the TAE cohort and 1036 d for the non-TAE cohort). Statistically lower associations were noted for the TAE group for any adverse event (hazard ratio 0.28, P = .037) and the composite outcome of hemorrhage or new seizure (hazard ratio 0.20, P = .029). CONCLUSION: For BAVMs at high risk for surgical resection, TAE can be performed safely and effectively. Patients treated with TAE had better outcomes than matched patients undergoing other combinations of treatment. TAE can be considered for BAVMs with high operative risk prior to radiosurgery or when no other treatment options are available.
Authors: F Settecase; S W Hetts; A D Nicholson; M R Amans; D L Cooke; C F Dowd; R T Higashida; V V Halbach Journal: AJNR Am J Neuroradiol Date: 2015-11-12 Impact factor: 3.825
Authors: C Stapf; J P Mohr; J Pile-Spellman; R R Sciacca; A Hartmann; H C Schumacher; H Mast Journal: J Neurol Neurosurg Psychiatry Date: 2002-09 Impact factor: 10.154
Authors: Juha A Hernesniemi; Reza Dashti; Seppo Juvela; Kristjan Väärt; Mika Niemelä; Aki Laakso Journal: Neurosurgery Date: 2008-11 Impact factor: 4.654
Authors: J P Mohr; Michael K Parides; Christian Stapf; Ellen Moquete; Claudia S Moy; Jessica R Overbey; Rustam Al-Shahi Salman; Eric Vicaut; William L Young; Emmanuel Houdart; Charlotte Cordonnier; Marco A Stefani; Andreas Hartmann; Rüdiger von Kummer; Alessandra Biondi; Joachim Berkefeld; Catharina J M Klijn; Kirsty Harkness; Richard Libman; Xavier Barreau; Alan J Moskowitz Journal: Lancet Date: 2013-11-20 Impact factor: 79.321
Authors: Faraz Behzadi; Daniel M Heiferman; Amy Wozniak; Benjamin Africk; Matthew Ballard; Joshua Chazaro; Brandon Zsigray; Matthew Reynolds; Douglas E Anderson; Joseph C Serrone Journal: J Cerebrovasc Endovasc Neurosurg Date: 2022-05-06